Summary

DelveInsight’s, Antibody Drug Conjugate (ADC)- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Antibody Drug Conjugate (ADC).This is a 500+ pages report providing insight on around 200 products and 60+ different technologies along with 160+ companies which are active in this field.  The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Antibody Drug Conjugate (ADC) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Antibody Drug Conjugate (ADC)-Pipeline Insights, 2015 Report covers the Antibody Drug Conjugate (ADC) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Antibody Drug Conjugate (ADC) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Antibody Drug Conjugate (ADC).

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• DelveInsight’s report provides an Antibody Drug Conjugate (ADC) Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators,  technology, development partner and chemical information
• Coverage of the Antibody Drug Conjugate (ADC) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Antibody Drug Conjugate (ADC) and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

• Complete Pipeline intelligence and complete understanding over therapeutics development for Antibody Drug Conjugate (ADC)
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Track your competitors and develop strategic initiatives to support your drug development activities
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business
• Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
• Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table of contents

Antibody Drug Conjugate (ADC) Overview
Antibody Drug Conjugate (ADC) Disease Associated
Antibody Drug Conjugate (ADC) Pipeline Therapeutics
Antibody Drug Conjugate (ADC) Therapeutics under Development by Companies
Antibody Drug Conjugate (ADC) Late Stage Products (Filed and Phase III)
Comparative Analysis
Antibody Drug Conjugate (ADC) Mid Clinical Stage Products (Phase II)
Comparative Analysis
Antibody Drug Conjugate (ADC)  Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis
Antibody Drug Conjugate (ADC) Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Antibody Drug Conjugate (ADC)– Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Antibody Drug Conjugate (ADC)– Discontinued Products
Antibody Drug Conjugate (ADC) – Dormant Products
Companies Involved in Therapeutics Development for Antibody Drug Conjugate (ADC)
Appendix
Methodology
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Antibody Drug Conjugate (ADC) by Therapy Area, 2015
Number of Products under Development for Antibody Drug Conjugate (ADC),2015
Number of Products under Development by Companies
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
Drug Candidates Profiles
Antibody Drug Conjugate (ADC) Assessment by Monotherapy Products
Antibody Drug Conjugate (ADC) Assessment by Combination Products
Antibody Drug Conjugate (ADC) Assessment by Route of Administration
Antibody Drug Conjugate (ADC) Assessment by Stage and Route of Administration
Antibody Drug Conjugate (ADC)Assessment by Molecule Type
Antibody Drug Conjugate (ADC) Assessment by Stage and Molecule Type
Antibody Drug Conjugate (ADC) Therapeutics – Discontinued Products
Antibody Drug Conjugate (ADC) Therapeutics – Dormant Products
Products under Development by Companies, 2015

List of Figures

Number of Products under Development for Antibody Drug Conjugate (ADC) by Therapy Area, 2015
Number of Products under Development for Antibody Drug Conjugate (ADC), 2015
Late Clinical Stage Products (Filed and Phase III), 2015
Mid Clinical Stage Products (Phase II), 2015
Early Clinical Stage Products (Phase I and IND Filed), 2015
Discovery and Pre-Clinical Stage Products, 2015
Antibody Drug Conjugate (ADC) Assessment by Monotherapy Products
Antibody Drug Conjugate (ADC), Assessment by Combination Products
Antibody Drug Conjugate (ADC), Assessment by Route of Administration
Antibody Drug Conjugate (ADC), Assessment by Stage and Route of Administration
Antibody Drug Conjugate (ADC), Assessment by Molecule Type
Antibody Drug Conjugate (ADC), Assessment by Stage and Molecule Type